Pam2 treatment synergizes with all classes of TLR9-stimulating CpG oligodeoxynucleotides.

<p>Mice were challenged with influenza 1 day after a single inhaled treatment with the described treatments. Shown are survival (<b>A</b>) and body weight (<b>B</b>) of mice through 22 days after challenge (mean ± s.d.). (n = 20 mice/group; * p<0.00001 vs. PBS treated, ** p = 0.0004 vs. PBS treated, † p = 0.01 vs. Pam2+ODN 2006 treated, † p = 0.1 vs Pam2+ODN 2006 treated).